These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. An autoimmune disease-associated CTLA4 splice variant lacking the B7 binding domain signals negatively in T cells. Vijayakrishnan L; Slavik JM; Illés Z; Rainbow D; Peterson LB; Sharpe AS; Wicker LS; Kuchroo VK Novartis Found Symp; 2005; 267():200-12; discussion 212-8. PubMed ID: 15999808 [TBL] [Abstract][Full Text] [Related]
3. Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice. Mourich DV; Oda SK; Schnell FJ; Crumley SL; Hauck LL; Moentenich CA; Marshall NB; Hinrichs DJ; Iversen PL Nucleic Acid Ther; 2014 Apr; 24(2):114-26. PubMed ID: 24494586 [TBL] [Abstract][Full Text] [Related]
4. Genetic evidence that the differential expression of the ligand-independent isoform of CTLA-4 is the molecular basis of the Idd5.1 type 1 diabetes region in nonobese diabetic mice. Araki M; Chung D; Liu S; Rainbow DB; Chamberlain G; Garner V; Hunter KM; Vijayakrishnan L; Peterson LB; Oukka M; Sharpe AH; Sobel R; Kuchroo VK; Wicker LS J Immunol; 2009 Oct; 183(8):5146-57. PubMed ID: 19783679 [TBL] [Abstract][Full Text] [Related]
5. B7-independent inhibition of T cells by CTLA-4. Chikuma S; Abbas AK; Bluestone JA J Immunol; 2005 Jul; 175(1):177-81. PubMed ID: 15972645 [TBL] [Abstract][Full Text] [Related]
6. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Freeman GJ; Gribben JG; Boussiotis VA; Ng JW; Restivo VA; Lombard LA; Gray GS; Nadler LM Science; 1993 Nov; 262(5135):909-11. PubMed ID: 7694363 [TBL] [Abstract][Full Text] [Related]
7. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Prud'homme GJ; Chang Y; Li X Hum Gene Ther; 2002 Feb; 13(3):395-406. PubMed ID: 11860706 [TBL] [Abstract][Full Text] [Related]
8. Induction of T cell anergy in the absence of CTLA-4/B7 interaction. Frauwirth KA; Alegre ML; Thompson CB J Immunol; 2000 Mar; 164(6):2987-93. PubMed ID: 10706686 [TBL] [Abstract][Full Text] [Related]
9. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Freeman GJ; Borriello F; Hodes RJ; Reiser H; Hathcock KS; Laszlo G; McKnight AJ; Kim J; Du L; Lombard DB Science; 1993 Nov; 262(5135):907-9. PubMed ID: 7694362 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. Fife BT; Griffin MD; Abbas AK; Locksley RM; Bluestone JA J Clin Invest; 2006 Aug; 116(8):2252-61. PubMed ID: 16886063 [TBL] [Abstract][Full Text] [Related]
11. CD28-independent costimulation of T cells in alloimmune responses. Yamada A; Kishimoto K; Dong VM; Sho M; Salama AD; Anosova NG; Benichou G; Mandelbrot DA; Sharpe AH; Turka LA; Auchincloss H; Sayegh MH J Immunol; 2001 Jul; 167(1):140-6. PubMed ID: 11418642 [TBL] [Abstract][Full Text] [Related]
13. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Salomon B; Lenschow DJ; Rhee L; Ashourian N; Singh B; Sharpe A; Bluestone JA Immunity; 2000 Apr; 12(4):431-40. PubMed ID: 10795741 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503 [TBL] [Abstract][Full Text] [Related]
15. T cells are the main cell type expressing B7-1 and B7-2 in the central nervous system during acute, relapsing and chronic experimental autoimmune encephalomyelitis. Cross AH; Lyons JA; San M; Keeling RM; Ku G; Racke MK Eur J Immunol; 1999 Oct; 29(10):3140-7. PubMed ID: 10540325 [TBL] [Abstract][Full Text] [Related]
16. Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1. Peach RJ; Bajorath J; Brady W; Leytze G; Greene J; Naemura J; Linsley PS J Exp Med; 1994 Dec; 180(6):2049-58. PubMed ID: 7964482 [TBL] [Abstract][Full Text] [Related]
17. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. Carreno BM; Bennett F; Chau TA; Ling V; Luxenberg D; Jussif J; Baroja ML; Madrenas J J Immunol; 2000 Aug; 165(3):1352-6. PubMed ID: 10903737 [TBL] [Abstract][Full Text] [Related]
18. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eagar TN; Karandikar NJ; Bluestone JA; Miller SD Eur J Immunol; 2002 Apr; 32(4):972-81. PubMed ID: 11920563 [TBL] [Abstract][Full Text] [Related]
19. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. Dahlén E; Hedlund G; Dawe K J Immunol; 2000 Mar; 164(5):2444-56. PubMed ID: 10679081 [TBL] [Abstract][Full Text] [Related]